Inogen, Inc (NASDAQ:INGN - Get Free Report) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $6.29 and traded as high as $7.38. Inogen shares last traded at $6.99, with a volume of 201,150 shares traded.
Analyst Ratings Changes
Separately, Freedom Capital raised Inogen to a "strong-buy" rating in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $11.00.
Get Our Latest Stock Report on Inogen
Inogen Stock Down 2.2%
The stock has a market cap of $191.04 million, a price-to-earnings ratio of -8.13 and a beta of 1.70. The company has a 50 day simple moving average of $6.29 and a 200 day simple moving average of $6.77.
Inogen (NASDAQ:INGN - Get Free Report) last issued its earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.10. The firm had revenue of $81.72 million during the quarter, compared to the consensus estimate of $82.00 million. Inogen had a negative return on equity of 11.56% and a negative net margin of 6.52%. As a group, analysts predict that Inogen, Inc will post -0.72 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. raised its stake in Inogen by 15.5% during the first quarter. Assenagon Asset Management S.A. now owns 51,028 shares of the medical technology company's stock worth $315,000 after acquiring an additional 6,843 shares in the last quarter. Hsbc Holdings PLC raised its stake in Inogen by 75.4% during the fourth quarter. Hsbc Holdings PLC now owns 60,482 shares of the medical technology company's stock worth $406,000 after acquiring an additional 25,998 shares in the last quarter. Corient Private Wealth LLC acquired a new position in Inogen during the fourth quarter worth about $84,000. Tudor Investment Corp ET AL raised its stake in Inogen by 10.1% during the fourth quarter. Tudor Investment Corp ET AL now owns 151,602 shares of the medical technology company's stock worth $1,019,000 after acquiring an additional 13,952 shares in the last quarter. Finally, Occudo Quantitative Strategies LP acquired a new position in Inogen during the fourth quarter worth about $145,000. Institutional investors and hedge funds own 89.94% of the company's stock.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc NASDAQ: INGN is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company's core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen's offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.
Inogen's flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
